稳定型心力衰竭患者和健康成年人中半乳糖凝集素-3及其他心脏生物标志物的短期和长期生物学变异性
Short- and Long-term Biologic Variability of Galectin-3 and Other Cardiac Biomarkers in Patients with Stable Heart Failure and Healthy Adults.
作者信息
Schindler Emily I, Szymanski Jeffrey J, Hock Karl G, Geltman Edward M, Scott Mitchell G
机构信息
Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology.
Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
出版信息
Clin Chem. 2016 Feb;62(2):360-6. doi: 10.1373/clinchem.2015.246553. Epub 2015 Nov 6.
BACKGROUND
Galectin-3 (Gal-3) has been suggested as a prognostic biomarker in heart failure (HF) patients that may better reflect disease progression than traditional markers, including B-type natriuretic peptide (BNP) and cardiac troponins. To fully establish the utility of any biomarker in HF, its biologic variability must be characterized.
METHODS
To assess biologic variability, 59 patients were prospectively recruited, including 23 male and 16 female patients with stable HF and 10 male and 10 female healthy individuals. Gal-3, BNP, and high-sensitivity cardiac troponin I (hs-cTnI) were assayed at 5 time points within a 3-week period to assess short-term biologic variability. Long-term (3-month) biologic variability was assessed with samples collected at enrollment and after 4, 8, and 12 weeks.
RESULTS
Among healthy individuals, mean short-term biologic variability, expressed as intraindividual CV (CVI), was 4.5% for Gal-3, 29.0% for BNP, and 14.5% for hs-cTnI; long-term biologic variability was 5.5% for Gal-3, 34.7% for BNP, and 14.7% for hs-cTnI. In stable HF patients, mean short-term biologic variability was 7.1% for Gal-3, 22.5% for BNP, and 8.5% for hs-cTnI, and mean long-term biologic variability was 7.7% for Gal-3, 27.6% for BNP, and 9.6% for hs-cTnI.
CONCLUSIONS
The finding that Gal-3 has minimal intraindividual biological variability adds to its potential as a useful biomarker in HF patients.
背景
半乳糖凝集素-3（Gal-3）被认为是心力衰竭（HF）患者的一种预后生物标志物，与包括B型利钠肽（BNP）和心肌肌钙蛋白在内的传统标志物相比，它可能能更好地反映疾病进展。为全面确定任何生物标志物在HF中的效用，必须对其生物学变异性进行表征。
方法
为评估生物学变异性，前瞻性招募了59名患者，包括23名男性和16名女性稳定HF患者以及10名男性和10名女性健康个体。在3周内的5个时间点检测Gal-3、BNP和高敏心肌肌钙蛋白I（hs-cTnI），以评估短期生物学变异性。通过在入组时以及4周、8周和12周后采集的样本评估长期（3个月）生物学变异性。
结果
在健康个体中，以个体内变异系数（CVI）表示的平均短期生物学变异性，Gal-3为4.5%，BNP为29.0%，hs-cTnI为14.5%；长期生物学变异性，Gal-3为5.5%，BNP为34.7%，hs-cTnI为14.7%。在稳定HF患者中，Gal-3的平均短期生物学变异性为7.1%，BNP为22.5%，hs-cTnI为8.5%，Gal-3的平均长期生物学变异性为7.7%，BNP为27.6%，hs-cTnI为9.6%。
结论
Gal-3个体内生物学变异性最小这一发现增加了其作为HF患者有用生物标志物的潜力。
Zotero 插件